Heart failure & cardiomyopathiesSecondary analysis
Prognostic utility of the Global Leadership Initiative on Sarcopenia model in older patients with heart failure: post hoc analysis of the FRAGILE-HF study
- Secondary analysis of the FRAGILE-HF prospective cohort study
- post hoc analysis
- multicentre
- prospective observational cohort
Authors' conclusion
The diagnosis of sarcopenia based on the GLIS model was associated with prognosis and impaired physical performance in older patients with heart failure.
Study context
- Population
- Older patients hospitalized for HF
- Participants
- 891 patients
- Comparison
- Sarcopenia and possible sarcopenia vs no sarcopenia
- Sarcopenian = 186
- Possible sarcopenian = 539
- Primary endpoint
- All-cause mortality
- Follow-up
- 2 years
Primary result
2-year all-cause mortality
Adjusted hazard ratio
3.38
95% CI 1.74–6.56
P < 0.001
Sarcopenia and possible sarcopenia (GLIS model) vs no sarcopenia
adjusted HR 3.38 (95% CI 1.74–6.56); P < 0.001
As reported in the abstract
Secondary outcomes
| Outcome | net reclassification improvement (95% CI) | P value |
|---|---|---|
| Prognostic discrimination, GLIS vs AWGS 2019 model | 0.269 (0.141–0.397) | P < 0.001 |
Impaired physical performance (incl. 6-min walk distance)
- Sarcopenia and possible sarcopenia significantly associated with impaired physical performance
Original publication
Prognostic utility of the Global Leadership Initiative on Sarcopenia model in older patients with heart failure: post hoc analysis of the FRAGILE-HF study. Eur J Prev Cardiol. Published 4 October 2025. doi:10.1093/eurjpc/zwaf636
Summarised from the published abstract; every number is checked against it